RU2743433C2 - Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией - Google Patents

Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией Download PDF

Info

Publication number
RU2743433C2
RU2743433C2 RU2018130330A RU2018130330A RU2743433C2 RU 2743433 C2 RU2743433 C2 RU 2743433C2 RU 2018130330 A RU2018130330 A RU 2018130330A RU 2018130330 A RU2018130330 A RU 2018130330A RU 2743433 C2 RU2743433 C2 RU 2743433C2
Authority
RU
Russia
Prior art keywords
cancer
salt
pharmaceutical composition
myricetin
agent
Prior art date
Application number
RU2018130330A
Other languages
English (en)
Russian (ru)
Other versions
RU2018130330A (ru
RU2018130330A3 (enExample
Inventor
Кристофер Дж. АРМСТРОНГ
Кевин Дж. КИМ
Лиза Мария Люсия ФЕМ
Ын Хе ПАК
Чжун ЧЖУН
Гуаньи ХУАН
Джозеф С. У
Сидни Пол ЭЛМЕР
Виват ВИСУТХИКРАИСЕЕ
Эйтон Майкл Дж. КАДАГ
Томас Бернард ФРИМАН
Пек Е ЛЮМ
Original Assignee
Сст Ii Ллк
Ауранса Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59496710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2743433(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сст Ii Ллк, Ауранса Инк. filed Critical Сст Ii Ллк
Publication of RU2018130330A publication Critical patent/RU2018130330A/ru
Publication of RU2018130330A3 publication Critical patent/RU2018130330A3/ru
Application granted granted Critical
Publication of RU2743433C2 publication Critical patent/RU2743433C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
RU2018130330A 2016-02-04 2017-02-03 Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией RU2743433C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662291480P 2016-02-04 2016-02-04
US62/291,480 2016-02-04
US201662348102P 2016-06-09 2016-06-09
US62/348,102 2016-06-09
PCT/US2017/016582 WO2017136774A1 (en) 2016-02-04 2017-02-03 Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021103727A Division RU2021103727A (ru) 2016-02-04 2017-02-03 Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией

Publications (3)

Publication Number Publication Date
RU2018130330A RU2018130330A (ru) 2020-03-05
RU2018130330A3 RU2018130330A3 (enExample) 2020-04-16
RU2743433C2 true RU2743433C2 (ru) 2021-02-18

Family

ID=59496710

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018130330A RU2743433C2 (ru) 2016-02-04 2017-02-03 Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
RU2021103727A RU2021103727A (ru) 2016-02-04 2017-02-03 Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021103727A RU2021103727A (ru) 2016-02-04 2017-02-03 Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией

Country Status (18)

Country Link
US (5) US10806716B2 (enExample)
EP (1) EP3411017A4 (enExample)
JP (2) JP7058396B2 (enExample)
KR (1) KR20180116298A (enExample)
CN (4) CN117100734A (enExample)
AU (1) AU2017214668B2 (enExample)
CA (1) CA3013768A1 (enExample)
CO (1) CO2018009132A2 (enExample)
HK (1) HK1257954A1 (enExample)
IL (2) IL284341B2 (enExample)
MX (4) MX2018009338A (enExample)
MY (1) MY197069A (enExample)
NZ (1) NZ745881A (enExample)
PH (1) PH12018501387A1 (enExample)
RU (2) RU2743433C2 (enExample)
SG (1) SG11201805375PA (enExample)
WO (1) WO2017136774A1 (enExample)
ZA (1) ZA201805741B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2856705C1 (ru) * 2025-03-20 2026-02-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") Способ снижения интенсивности свободнорадикальных и апоптотических процессов при диклофенак-индуцированной кардиотоксичности

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
CN117100734A (zh) 2016-02-04 2023-11-24 Sct二代有限责任公司 一种拓扑异构酶ii抑制剂及其用途和药物组合物
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11534399B2 (en) * 2018-04-23 2022-12-27 Inspirmed Corp. Inhalable liposomal sustained release composition for use in treating pulmonary diseases
PL429672A1 (pl) * 2019-04-17 2020-10-19 Bioxan Spółka Z Ograniczoną Odpowiedzialnością Preparat zawierający ksantohumol i zastosowanie ksantohumolu
KR102349477B1 (ko) * 2019-08-30 2022-01-10 (주)프론트바이오 바이구아나이드 계열 화합물 및 플라본, 하이드록시플라본, 플라바논, 플라본 유도체, 하이드록시플라본 유도체, 플라바논 유도체의 복합제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US20230035491A1 (en) * 2019-12-15 2023-02-02 Baruch S. Blumberg Institute Methods, kits and compositions for reducing cardiotoxicity associated with cancer therapies
CN111228271A (zh) * 2020-03-31 2020-06-05 青岛泱深生物医药有限公司 含拉帕替尼的药物组合物及其应用
WO2022089590A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类酪氨酸激酶抑制剂复盐化合物及其制备方法和应用
CN112353944A (zh) * 2020-11-23 2021-02-12 湖州师范学院求真学院 一种包括化合物f-b的抗癌联合用药组合物
CN112386704B (zh) * 2020-11-23 2023-07-04 中国科学院西北高原生物研究所 一种包括化合物f-c的抗癌联合用药组合物
CN112438977B (zh) * 2020-12-02 2023-05-19 贵州大学 一种含苯并咪唑的杨梅素衍生物、制备方法及用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN113143925B (zh) * 2021-04-16 2022-03-25 浙江大学智能创新药物研究院 盐酸二甲双胍在制备治疗克唑替尼心脏毒性制剂中的应用
CN113304275B (zh) * 2021-06-04 2023-04-11 仲恺农业工程学院 一种二氢杨梅素修饰dna药物递送系统、纳米载药系统及制备方法和应用
US11938127B2 (en) 2021-09-28 2024-03-26 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent proliferative disorders
JP2024540167A (ja) * 2021-11-05 2024-10-31 ビミュオ ゲーエムベーハー 梗塞損傷の改善および処置
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers
CN115290608B (zh) * 2021-12-22 2024-08-13 温州医科大学 快速检测米托蒽醌或阿霉素的试剂及检测方法
KR102998875B1 (ko) 2022-10-21 2026-07-31 한국식품연구원 냉이 추출물을 유효성분으로 함유하는 심근 손상의 개선, 예방 또는 치료용 조성물
US11903944B1 (en) 2023-05-30 2024-02-20 King Faisal University Experimental model using pazopanib-induced cardiotoxicity
CN116606273B (zh) * 2023-07-19 2023-09-26 云南中医药大学 具有美白作用的黄花夹竹桃黄酮的制备方法
WO2025117853A1 (en) * 2023-11-29 2025-06-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to ameliorate drug-induced long qt syndrome
CN117582432A (zh) * 2023-12-01 2024-02-23 浙江省农业科学院 杨梅黄酮在制备预防和/或治疗心脏毒性的药物中的应用
CN117958187B (zh) * 2024-01-10 2026-03-24 青岛大学 阿霉素和拉帕替尼在构建斑马鱼心脏毒性损伤模型中的应用及药物筛选方法
CN119499237B (zh) * 2024-12-10 2026-01-27 阜外华中心血管病医院 羟基芫花素在制备防治抗肿瘤药物诱导的心脏毒性的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080855A1 (en) * 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US20130095124A1 (en) * 2009-04-20 2013-04-18 Susan Szathmary Compositions for transfection of biomolecules into cells
WO2015138186A2 (en) * 2014-03-12 2015-09-17 Wake Forest University Health Sciences Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214308A2 (en) 1999-09-23 2002-06-19 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
WO2007059111A2 (en) 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
MX339451B (es) * 2008-04-03 2016-05-27 Cognate 3 Llc Composiciones y metodos para inmunoterapia.
CN101485655B (zh) * 2009-02-12 2012-08-22 华南理工大学 二氢杨梅素在制备防治肿瘤放化疗不良反应的药物的应用
CN102274236B (zh) * 2010-06-13 2013-11-06 上海市第六人民医院 一种防治蒽环类抗生素心脏毒性的药物及其应用
CN102697795B (zh) * 2011-07-01 2014-06-18 成都医学院 一种抗肿瘤联合用药物
US20150018294A1 (en) 2012-02-07 2015-01-15 Arrigo DE BENEDETTI Modulators of tousled kinase in cellular processes
WO2014077409A1 (ja) 2012-11-19 2014-05-22 国立大学法人東京大学 スニチニブの副作用軽減剤
CN103315993A (zh) * 2013-06-22 2013-09-25 浙江大学 二氢杨梅素在制备抑制阿霉素心脏毒性药物中的应用
KR20150084535A (ko) * 2014-01-14 2015-07-22 건국대학교 산학협력단 피세틴의 수용성 및 생체이용률을 개선하는 조성물 및 그 방법
CN117100734A (zh) 2016-02-04 2023-11-24 Sct二代有限责任公司 一种拓扑异构酶ii抑制剂及其用途和药物组合物
CN107595802B (zh) * 2017-09-27 2021-04-23 浙江海洋大学 杨梅素在制备抗阿霉素心脏毒性保护制剂中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080855A1 (en) * 2000-04-27 2001-11-01 Geron Corporation Telomerase inhibitors and methods of their use
US20130095124A1 (en) * 2009-04-20 2013-04-18 Susan Szathmary Compositions for transfection of biomolecules into cells
WO2015138186A2 (en) * 2014-03-12 2015-09-17 Wake Forest University Health Sciences Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
KAISEROVA et al. Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase // Biochimica et Biophysica Acta. - 2007. - Vol. 1772. - P. 1065-1074. *
LEFRAK E.A. et al. A clinicopathologic analysis of adriamycin cardiotoxicity // Cancer. - 1973. - Vol. 32(2). - P. 302-314. *
LEFRAK E.A. et al. A clinicopathologic analysis of adriamycin cardiotoxicity // Cancer. - 1973. - Vol. 32(2). - P. 302-314. SWAIN S.M. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer // Journal of Clinical Oncology. - 1997. - Vol. 15(4). - P. 1318-1332. *
MIRZA Y.A. et al. Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report // Case Rep Dermatol. - 2015. - Vol. 7(1). - P. 17-19. *
MIRZA Y.A. et al. Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report // Case Rep Dermatol. - 2015. - Vol. 7(1). - P. 17-19. NOWIS D. et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib // Am J Pathol. - 2010. - Vol. 176(6). - P. 2658-2668. SOUCEK P. et al. New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals // Anticancer Drugs. - 2011. - Vol. 22(2). - P. 176-184. KAISEROVA et al. Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase // Biochimica et Biophysica Acta. - 2007. - Vol. 1772. - P. 1065-1074. XIAO J. et al. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro // Toxicology. - 2012. - Vol. 292. - P. 53-62. *
NOWIS D. et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib // Am J Pathol. - 2010. - Vol. 176(6). - P. 2658-2668. *
SOUCEK P. et al. New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals // Anticancer Drugs. - 2011. - Vol. 22(2). - P. 176-184. *
SWAIN S.M. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer // Journal of Clinical Oncology. - 1997. - Vol. 15(4). - P. 1318-1332. *
XIAO J. et al. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro // Toxicology. - 2012. - Vol. 292. - P. 53-62. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2856705C1 (ru) * 2025-03-20 2026-02-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") Способ снижения интенсивности свободнорадикальных и апоптотических процессов при диклофенак-индуцированной кардиотоксичности

Also Published As

Publication number Publication date
RU2018130330A (ru) 2020-03-05
HK1257954A1 (zh) 2019-11-01
MX2021009540A (es) 2022-12-14
ZA201805741B (en) 2022-12-21
US20170224654A1 (en) 2017-08-10
CN117100734A (zh) 2023-11-24
PH12018501387A1 (en) 2019-02-27
US10806716B2 (en) 2020-10-20
US11166936B2 (en) 2021-11-09
CN117045793A (zh) 2023-11-14
US20190175544A1 (en) 2019-06-13
MX2022001540A (es) 2022-03-02
IL284341B2 (en) 2023-09-01
US11786503B2 (en) 2023-10-17
EP3411017A1 (en) 2018-12-12
JP2019504100A (ja) 2019-02-14
RU2018130330A3 (enExample) 2020-04-16
MX2018009338A (es) 2019-01-10
CO2018009132A2 (es) 2018-12-14
MX2022001541A (es) 2022-03-02
AU2017214668A1 (en) 2018-09-20
IL260972B (en) 2021-07-29
US10874633B2 (en) 2020-12-29
WO2017136774A1 (en) 2017-08-10
BR112018015979A2 (en) 2018-12-18
AU2017214668B2 (en) 2022-12-08
MY197069A (en) 2023-05-24
CN117159571A (zh) 2023-12-05
JP7058396B2 (ja) 2022-04-22
KR20180116298A (ko) 2018-10-24
EP3411017A4 (en) 2020-02-12
IL284341A (en) 2021-07-29
RU2021103727A (ru) 2021-03-17
JP2022017518A (ja) 2022-01-25
SG11201805375PA (en) 2018-07-30
US20210121436A1 (en) 2021-04-29
US20220133684A1 (en) 2022-05-05
US20200253920A1 (en) 2020-08-13
CA3013768A1 (en) 2017-08-10
CN108697646A (zh) 2018-10-23
NZ745881A (en) 2023-04-28
IL284341B1 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
US11786503B2 (en) Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
EP2522395A1 (en) Combination therapies using HDAC inhibitors
US20130184214A1 (en) Pharmaceutical compositions and methods
US20260027088A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
AU2014248928B2 (en) Onapristone polymorphic forms and methods of use
EP4045027A1 (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
US20160000762A1 (en) Improving cognitive function
WO2020234828A1 (en) Oxathiazin compounds for inhibiting gapdh
US20200281918A1 (en) Calcium release-activated calcium channel modulators for treating hematological and solid cancers
EP3697417A1 (en) Crac channel modulators for treating esophageal cancer
BR112018015979B1 (pt) Composições farmacêuticas e métodos para combater a cardiotoxicidade induzida por quimioterapia
KR20240037889A (ko) E3 리가아제 억제제 및 이의 사용 방법
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы
AU2015201968A1 (en) Combination therapies using hdac inhibitors